Benitec Sale Purchase Of Stock vs End Period Cash Flow Analysis

BNTC Stock

USD 10.09 0.36 3.70%

Benitec Biopharma financial indicator trend analysis is way more than just evaluating Benitec Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Benitec Biopharma is a good investment. Please check the relationship between Benitec Biopharma Sale Purchase Of Stock and its End Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Sale Purchase Of Stock vs End Period Cash Flow

Sale Purchase Of Stock vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Benitec Biopharma Sale Purchase Of Stock account and End Period Cash Flow. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Benitec Biopharma's Sale Purchase Of Stock and End Period Cash Flow is 0.16. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Benitec Biopharma Ltd, assuming nothing else is changed. The correlation between historical values of Benitec Biopharma's Sale Purchase Of Stock and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of Benitec Biopharma Ltd are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Sale Purchase Of Stock i.e., Benitec Biopharma's Sale Purchase Of Stock and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.16

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Sale Purchase Of Stock

End Period Cash Flow

Most indicators from Benitec Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Benitec Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

At present, Benitec Biopharma's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.99, whereas Sales General And Administrative To Revenue is forecasted to decline to 30.27.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	17.9M	19.2M	22.4M	13.5M
Cost Of Revenue	9K	381K	108K	202.0K

Total Operating Expenses Cost Of Revenue

Benitec Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Short Term Investments	Non Current Liabilities Total	Net Invested Capital	Net Working Capital
Total Assets		0.42	0.45	0.99	-0.38	-1.0	-0.38	0.17	1.0	-0.37	1.0	-0.21	-0.07	0.71	0.17	-0.15	0.39	0.27	1.0	-0.07	-0.28	-0.01	-0.16	-0.22	0.93	0.93
Other Current Liab	0.42		0.92	0.33	0.4	-0.4	-0.95	0.16	0.44	0.46	0.44	-0.19	-0.7	0.91	-0.49	0.6	0.93	0.92	0.41	-0.7	0.49	-0.8	-0.28	-0.21	0.53	0.53
Total Current Liabilities	0.45	0.92		0.36	0.39	-0.43	-0.92	0.52	0.47	0.42	0.47	-0.13	-0.64	0.91	-0.5	0.59	1.0	0.92	0.44	-0.64	0.46	-0.8	-0.02	0.11	0.56	0.56
Total Stockholder Equity	0.99	0.33	0.36		-0.45	-0.99	-0.29	0.13	0.99	-0.43	0.99	-0.2	0.0	0.64	0.24	-0.23	0.29	0.18	1.0	0.0	-0.34	0.08	-0.16	-0.24	0.91	0.91
Property Plant And Equipment Net	-0.38	0.4	0.39	-0.45		0.39	-0.54	0.07	-0.35	0.98	-0.35	-0.18	-0.76	0.21	-0.59	0.45	0.46	0.57	-0.4	-0.76	0.89	-0.74	-0.01	0.3	-0.16	-0.16
Net Debt	-1.0	-0.4	-0.43	-0.99	0.39		0.36	-0.17	-1.0	0.37	-1.0	0.24	0.08	-0.7	-0.18	0.16	-0.37	-0.26	-1.0	0.08	0.27	0.0	0.19	0.22	-0.92	-0.92
Retained Earnings	-0.38	-0.95	-0.92	-0.29	-0.54	0.36		-0.21	-0.41	-0.6	-0.41	0.23	0.83	-0.9	0.59	-0.63	-0.93	-0.96	-0.36	0.83	-0.62	0.85	0.21	0.03	-0.52	-0.51
Accounts Payable	0.17	0.16	0.52	0.13	0.07	-0.17	-0.21		0.17	0.04	0.17	0.16	-0.01	0.29	-0.2	0.24	0.49	0.31	0.17	-0.01	0.08	-0.27	0.58	0.69	0.2	0.2
Cash	1.0	0.44	0.47	0.99	-0.35	-1.0	-0.41	0.17		-0.33	1.0	-0.25	-0.12	0.73	0.15	-0.13	0.41	0.31	1.0	-0.12	-0.24	-0.05	-0.19	-0.22	0.94	0.94
Non Current Assets Total	-0.37	0.46	0.42	-0.43	0.98	0.37	-0.6	0.04	-0.33		-0.33	-0.16	-0.8	0.24	-0.64	0.56	0.49	0.59	-0.38	-0.8	0.9	-0.75	-0.04	0.3	-0.14	-0.15
Cash And Short Term Investments	1.0	0.44	0.47	0.99	-0.35	-1.0	-0.41	0.17	1.0	-0.33		-0.24	-0.12	0.73	0.15	-0.13	0.41	0.31	1.0	-0.12	-0.24	-0.05	-0.19	-0.22	0.94	0.94
Net Receivables	-0.21	-0.19	-0.13	-0.2	-0.18	0.24	0.23	0.16	-0.25	-0.16	-0.24		0.47	-0.23	-0.42	-0.16	-0.15	-0.27	-0.2	0.47	-0.03	0.07	0.78	0.27	-0.07	-0.07
Common Stock Total Equity	-0.07	-0.7	-0.64	0.0	-0.76	0.08	0.83	-0.01	-0.12	-0.8	-0.12	0.47		-0.6	0.51	-0.59	-0.68	-0.81	-0.05	1.0	-0.78	0.81	0.34	-0.07	-0.21	-0.2
Common Stock Shares Outstanding	0.71	0.91	0.91	0.64	0.21	-0.7	-0.9	0.29	0.73	0.24	0.73	-0.23	-0.6		-0.37	0.35	0.88	0.86	0.7	-0.6	0.35	-0.68	-0.2	-0.15	0.8	0.8
Inventory	0.17	-0.49	-0.5	0.24	-0.59	-0.18	0.59	-0.2	0.15	-0.64	0.15	-0.42	0.51	-0.37		-0.45	-0.52	-0.54	0.18	0.51	-0.78	0.75	-0.35	-0.37	-0.13	-0.12
Other Current Assets	-0.15	0.6	0.59	-0.23	0.45	0.16	-0.63	0.24	-0.13	0.56	-0.13	-0.16	-0.59	0.35	-0.45		0.62	0.64	-0.16	-0.59	0.41	-0.53	-0.08	0.22	-0.11	-0.12
Total Liab	0.39	0.93	1.0	0.29	0.46	-0.37	-0.93	0.49	0.41	0.49	0.41	-0.15	-0.68	0.88	-0.52	0.62		0.94	0.37	-0.68	0.52	-0.83	-0.04	0.11	0.5	0.49
Property Plant And Equipment Gross	0.27	0.92	0.92	0.18	0.57	-0.26	-0.96	0.31	0.31	0.59	0.31	-0.27	-0.81	0.86	-0.54	0.64	0.94		0.26	-0.81	0.62	-0.89	-0.18	-0.01	0.42	0.41
Total Current Assets	1.0	0.41	0.44	1.0	-0.4	-1.0	-0.36	0.17	1.0	-0.38	1.0	-0.2	-0.05	0.7	0.18	-0.16	0.37	0.26		-0.05	-0.29	0.01	-0.16	-0.22	0.93	0.93
Common Stock	-0.07	-0.7	-0.64	0.0	-0.76	0.08	0.83	-0.01	-0.12	-0.8	-0.12	0.47	1.0	-0.6	0.51	-0.59	-0.68	-0.81	-0.05		-0.78	0.81	0.34	-0.07	-0.21	-0.2
Property Plant Equipment	-0.28	0.49	0.46	-0.34	0.89	0.27	-0.62	0.08	-0.24	0.9	-0.24	-0.03	-0.78	0.35	-0.78	0.41	0.52	0.62	-0.29	-0.78		-0.87	0.04	0.26	-0.01	-0.02
Net Tangible Assets	-0.01	-0.8	-0.8	0.08	-0.74	0.0	0.85	-0.27	-0.05	-0.75	-0.05	0.07	0.81	-0.68	0.75	-0.53	-0.83	-0.89	0.01	0.81	-0.87		0.02	-0.13	-0.24	-0.24
Short Term Investments	-0.16	-0.28	-0.02	-0.16	-0.01	0.19	0.21	0.58	-0.19	-0.04	-0.19	0.78	0.34	-0.2	-0.35	-0.08	-0.04	-0.18	-0.16	0.34	0.04	0.02		0.71	-0.07	-0.07
Non Current Liabilities Total	-0.22	-0.21	0.11	-0.24	0.3	0.22	0.03	0.69	-0.22	0.3	-0.22	0.27	-0.07	-0.15	-0.37	0.22	0.11	-0.01	-0.22	-0.07	0.26	-0.13	0.71		-0.13	-0.14
Net Invested Capital	0.93	0.53	0.56	0.91	-0.16	-0.92	-0.52	0.2	0.94	-0.14	0.94	-0.07	-0.21	0.8	-0.13	-0.11	0.5	0.42	0.93	-0.21	-0.01	-0.24	-0.07	-0.13		1.0
Net Working Capital	0.93	0.53	0.56	0.91	-0.16	-0.92	-0.51	0.2	0.94	-0.15	0.94	-0.07	-0.2	0.8	-0.12	-0.12	0.49	0.41	0.93	-0.2	-0.02	-0.24	-0.07	-0.14	1.0

Click cells to compare fundamentals

Benitec Biopharma Account Relationship Matchups

Benitec Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.6M	21.4M	6.0M	4.5M	52.2M	54.8M
Other Current Liab	662K	882K	1.9M	2.6M	3.3M	3.5M
Total Current Liabilities	1.1M	1.4M	2.5M	4.0M	4.9M	5.2M
Total Stockholder Equity	10.2M	20.0M	2.9M	202K	47.2M	49.6M
Property Plant And Equipment Net	769K	577K	993K	613K	449K	517.7K
Net Debt	(9.4M)	(19.6M)	(3.3M)	(1.9M)	(50.6M)	(48.1M)
Retained Earnings	(116.6M)	(130.1M)	(148.3M)	(167.9M)	(190.3M)	(199.8M)
Accounts Payable	282K	274K	422K	1.1M	1.4M	801.4K
Cash	9.8M	19.8M	4.1M	2.5M	50.9M	53.4M
Non Current Assets Total	778K	771K	1.2M	735K	536K	583.5K
Cash And Short Term Investments	9.8M	19.8M	4.1M	2.5M	50.9M	53.4M
Net Receivables	59K	25K	3K	55K	229K	217.6K
Common Stock Shares Outstanding	60.1K	252.7K	480.7K	1.4M	4.1M	4.3M
Liabilities And Stockholders Equity	11.6M	21.4M	6.0M	4.5M	52.2M	54.8M
Inventory	1.0	948K	1.8	13K	63K	59.9K
Other Current Assets	1K	814K	755K	1.3M	579K	480.1K
Other Stockholder Equity	128.8M	151.6M	152.5M	168.9M	238.4M	250.3M
Total Liab	1.3M	1.4M	3.1M	4.3M	5.0M	5.2M
Property Plant And Equipment Gross	769K	577K	993K	1.9M	1.9M	1.9M
Total Current Assets	10.8M	20.6M	4.8M	3.7M	51.7M	54.3M
Accumulated Other Comprehensive Income	(2.0M)	(1.5M)	(1.2M)	(830K)	(892K)	(847.4K)
Property Plant Equipment	769K	577K	993K	613K	705.0K	511.4K
Net Tangible Assets	10.2M	20.0M	2.9M	202K	181.8K	172.7K
Non Currrent Assets Other	(148K)	194K	160K	122K	87K	61.7K
Other Assets	9K	194K	160K	122K	140.3K	147.3K
Non Current Liabilities Total	213K	1.1M	559K	284K	38K	36.1K
Capital Lease Obligations	405K	213K	811K	559K	284K	249.9K
Short Term Debt	192K	213K	252K	275K	284K	298.2K
Short Long Term Debt Total	405K	213K	811K	559K	284K	277.7K
Net Invested Capital	10.2M	20.0M	2.9M	202K	47.2M	49.6M
Net Working Capital	9.7M	19.2M	2.3M	(249K)	46.8M	49.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:

How To Invest In Benitec

Details

Is Benitec Stock a good investment?

Details

What is Benitec Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.51)

Revenue Per Share

0.003

Quarterly Revenue Growth

0.125

Return On Assets

(0.50)

Return On Equity

(0.92)

The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Benitec Sale Purchase Of Stock vs End Period Cash Flow Analysis

Sale Purchase Of Stock vs End Period Cash Flow

Sale Purchase Of Stock vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Sale Purchase Of Stock

End Period Cash Flow

Benitec Biopharma fundamental ratios Correlations

Benitec Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Benitec Biopharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Net Debt	- 0.99	Total Stockholder Equity
Property Plant And Equipment Gross	- 0.96	Retained Earnings